Weight loss drugs in development Incretin-based therapy GLP1-related drug candidates. 6% of their body weight after 48 weeks, compared to the 2. The rapidly realized blockbuster sales of the leading drugs in the space, Novo Nordisk ’s Wegovy and Eli Lilly Bjerre Knudsen had been thinking about pursuing significant weight loss with these drugs since she noticed the literature around weight changes in treated animals, including in papers in 1995 and 1996. 1146/annurev-pharmtox-061324-011832. Food and Drug Administration (FDA) to treat type 2 diabetes in May 2022, and given the data in those studies showing that people taking the drug also lost weight New drugs in development may one day be taken orally, Greenberg says. That could translate Following the success of GLP-1 agonists, a new generation of weight loss drugs is coming down the research pipeline. From promising new oral medications to innovative approaches mimicking exercise, these Viking Therapeutics’ dual GLP-1 and GIP agonist produced weight loss of up to 14. That month, on a scheduled investor day, the company also intends to reveal more about its obesity drug development strategy. The number of people without diabetes taking a GLP-1 drug The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly , opens new tab and Novo Nordisk , opens new tab that will offer patients a New weight loss drugs. These ‘GLP-1 agonists’ mimic a natural gut Moving forward, those companies looking to stake a claim in the therapeutic weight loss market—or to retain their competitive edge—are approaching drug development The landscape of weight loss drugs is evolving with exciting advancements in research and development. We also manually screened the citations of previous reviews on the topic. targets the androgen hormones that play a role in body development and SURMOUNT 1 tested tirzepatide at 5, 10, or 15 mg weekly for 72 weeks, and found that the 15 mg formulation produced a 17. New weight loss drugs are changing the narrative on obesity, with a push from pharma. Pfizer announced that it has selected its preferred once-daily modified release formulation of danuglipron, a move that is significant in the obesity drug’s development. M Researchers found that patients who got the highest dose of the drug lost on average 15. One study compared GLP-1RAs against another weight loss drug, bupropion-naltrexone, revealing GLP-1RAs led to a 3. The firm noted that the FDA’s document addresses loss of lean muscle mass accompanying weight loss, which has been raised as a concern for both Novo Nordisk’s and Eli Lilly’s blockbuster GLP-1 drugs. 167 Amycretin was uptitrated to 5 mg by 28 weeks, at which point patients lost 16. Authors Weight Loss* / drug effects Substances Anti-Obesity Agents Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile The company plans to conduct dose optimization studies with a focus on the preferred formulation to inform the registration enabling studies Pfizer Inc. , 2023). Here are potential winners and losers. By Reuters. This competition may finally lead to lower prices and greater supplies of these highly Perhaps the most important development that occurred this year was the FDA’s approval of Eli Lilly’s Zepbound for obesity in November. Weight loss is typically associated with loss not only of fat but also skeletal muscle (up to 25% [68]) and bone mineral density, although A steady stream of weight loss drugs, which mimic naturally occurring hormones, are in the pipeline. The results were competitive to the Big Pharma According to IQVIA, the number of clinical trials for obesity drugs in 2023 was up by 68% from 2022, with 124 drugs in active development—of these, 40% are agonists of either the GLP-1 or glucose-dependent insulinotropic This year, celebrity gossip, a national shortage and eyebrow-raising clinical trials made household names of weight-loss and diabetes drugs like Ozempic, Wegovy and Mounjaro. The mechanism of action of GLP-1 agonists for weight loss is multi-factorial, and the improvement of intestinal, brain and systemic insulin sensitivity all contribute to the SGLT 1/2 inhibitors and AMPK/Sirt1 activators produce weight loss with mild adverse events but have yet to be investigated in large trials of long duration. S. There are several weight loss drugs currently in the works. Introduction : Obesity is compounded by a neurobiology that is resistant to weight loss. The drug’s active ingredient is tirzepatide, which By the mid-2010s, one such drug, liraglutide, was capable of eliciting a loss in body weight of about 8% on average, 5 percentage points more than for people taking a placebo—clinically relevant Roche plans to start a mid-stage trial this year combining the drug and its own GLP-1 weight-loss drug candidate CT-388. As is apparent in several non-selective centrally-acting medications, off target effects in the brain (in this case depression and suicidal ideation) can derail This new drug, liraglutide, approved as Victoza in 2010 in the United States, was better for weight-loss than Byetta (typically 10% weight-loss), but still needed daily injections. Efforts to model the weight-loss drugs’ future impact are highly speculative for a physician and economist at the Organisation for Economic Co-operation and Development (OECD) in Paris, says The success of GLP-1 medications is also encouraging collaborations and partnerships for new drug development, potentially leading to more innovative treatment options. Oral GLP-1 RA are Table 2 Weight loss drugs in clinical development. However, there was a problem: GLP-1 quickly disappears from the human body, positing difficulties in drug development. 22-fold higher risk of bowel obstruction. Some are pills, which may be easier to take than the current injected drugs. This inspired the development of the drug tirzepatide, marketed by Eli Lilly as Mounjaro for diabetes and as Zepbound for obesity, which By the mid-2010s, one such drug, liraglutide, was capable of eliciting a loss in body weight of about 8% on average, 5 percentage points more than for people taking a placebo 6 — clinically The history of weight-loss drug development is a tumultuous one. STAT+. 1% within four weeks in obese patients without diabetes in a Phase I trial, Roche said in a Catalytic events for obesity drugs after 2024. The US Food and Drug Administration (FDA) has published draft guidance for sponsors developing drugs and biologics for weight reduction for patients who are obese. Next-gen weight-loss drugs like CagriSema and UBT251 could hit shelves within a year, promising more effective obesity and diabetes treatments. e. At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. in both drug and placebo arms). Though these were still relatively rare, the number of people taking these drugs around Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology Annu Rev Pharmacol Toxicol. According to Reci, Eli Lily’s retatrutide (LY3437943), a triple agonist targeting GIPR, GLP-1R, and glucagon receptor (GCGR), is demonstrating superior weight loss benefits, Due to the limited availability of weight loss drugs in the country, some of the pharma firms like Dr. As consumer interest in weight loss drugs peaks, researchers are actively investigating numerous oral prescriptions in clinical trials—with oral semaglutide, orforglipron, and danuglipron currently at the forefront of advancements. It is a reversible inhibitor of lipases, which exerts its therapeutic activity in the lumen of the stomach and the small intestine by binding covalently to the active serine residue site of This guidance provides recommendations to industry regarding the development of drugs and biological products regulated within the Developing Drugs and Biological Products for Weight Reduction All the new weight loss drugs mimic the action of a naturally occurring substance called glucagon-like peptide 1 (GLP-1). The 10% weight loss in 24 weeks induced by the centrally acting drug Tesofensine is promising, but at this time the product launch is anticipated only in Mexico and Argentina. targets the androgen hormones that play a role in body development and New weight loss drugs could be developed much faster if Roche gets its way As a result, the company said in July that it is fast-tracking the development of its weight loss drug candidates. For individuals who have not responded Moving forward, those companies looking to stake a claim in the therapeutic weight loss market—or to retain their competitive edge—are approaching drug development from three angles: layering on additional targets, interrogating new ways of delivery and refining their formulas to either dampen unwanted side effects or boost potential protective effects. drug development. Recently developed drugs and those currently under development have been shown to reduce body weight by more than 10% and are expected to reduce obesity-related complications. Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing The revelation led the US Food and Drug Administration to approve the first GLP-1 drug for weight loss in 2014. The latest contender takes a Trojan horse Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts energy use, and enhances insulin sensitivity without causing nausea or muscle loss. Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. By 36 weeks, the amycretin dose had been bumped up to 20 mg, resulting in Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. The agency frames the decline of muscle mass as an expected and non-adverse outcome of weight loss. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management results in 15–17% mean weight loss (WL) with evidence of cardioprotection. Beyond obesity, Roche is interested in how incretin drugs may curb systemic inflammation, making them potentially worth exploring as part of TUESDAY, April 1, 2025 -- The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says. Weight loss drugs in clinical development. doi: 10. Therefore, the development of pharmacotherapies to address the pathology underlying the dysregulation of energy homeostasis is critical. Figure 4. Like all clinical trials in obesity drug development programs to date, a structured, multicomponent lifestyle intervention was provided to all participants (i. 3%. Credit: Shelby Knowles/Bloomberg via Getty From alcoholism to Parkinson’s, scientists are studying the mechanisms behind the broad clinical potential of weight-loss drugs. Called liraglutide and sold under the brand name Saxenda, the weekly injectable led Pfizer's formulation development of once-daily danuglipron, its mechanism, and market expectations in the competitive landscape of weight-loss drugs. 7% after 13 weeks of treatment in data released in February. GLP-1 related drugs. Glyscend Therapeutics is one company looking to develop a new generation of orally For weight loss medications under development, we searched the clinicaltrials. 09-fold higher risk of pancreatitis and a 4. Pharmaceuticals. Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy. 7% achieved >20% weight loss. There was also a 9. From a lizard toxin to Ozempic Meanwhile, Danish pharmaceutical company Novo Nordisk had been developing a long-acting GLP-1-mimicking drug, as it had done for insulin in the past. In a study, participants who took semaglutide for over a year lost more than twice as much body weight on average — almost 16% — as did people taking an older weight-loss drug that mimics the Orlistat. This discovery may pave the way for effective treatments for obesity and type 2 diabetes. We have conducted multiple DIO mouse studies characterizing the efficacy of various weight loss drugs, including semaglutide and tirzepatide, The expertise comes from successfully profiling numerous anti-obesity drug Competition is on the way: Dozens of experimental new weight-loss medications are in development as biotech companies race to get a slice of a market forecast to be worth $100 billion. and to stop the drug in 17 This guidance provides recommendations to industry regarding the development of drugs and 111 Although weight loss is associated with the aforementioned clinical benefits, some prospective The overarching objective of the guidance, titled Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction, is to provide a structured framework for the development of safe and effective weight management therapies, with a particular focus on long-term weight reduction and the associated health benefits, according to Those drugs have stunned longtime obesity researchers, who had all but given up on ever seeing safe and effective weight loss drugs. Some of the experimental drugs Research has shown that drugs targeting NK2R can achieve healthier weight loss that is not possible with current obesity medications. This Muscle loss is a big concern for people on anti-obesity medications such as semaglutide. Orlistat was approved for long-term weight management by the Food and Drug Administration (FDA) in 1999 and the Korea Ministry of Food and Drug Safety in 2000 (Jeon et al. In the past five years or so, two GLP-1 receptor agonists that lead to substantial weight loss have Every week seemed to bring a new development: soaring sales, widespread shortages, Cook believes the FDA will declare an end to the shortage of weight-loss drugs in 2025, but the agency will Weight-loss treatments have quickly emerged as one of the hottest areas for R&D in the pharmaceutical industry. Two of the most prescribed drugs for weight loss are GLP-1s: Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide). Mounjaro was approved by the U. By Elaine Chen and Matthew Herper. Unlike oral semaglutide, which must be taken an hour before eating food or taking other medications, Pfizer’s twice-daily tablet can be taken alongside food. But Dr. San Diego-based Viking Therapeutics marked itself as a serious competitor in the weight loss drug market in February after revealing promising data from a mid-stage trial of experimental drug Roche plans to start a mid-stage trial this year combining the drug and its own GLP-1 weight-loss drug candidate CT-388. 2025 Jan;65(1):191-213. This is due to a variety of reasons, including popular marketing The pharmaceutical company is advancing several drugs for weight loss. March 5, 2023. However, many other drugmakers are working on their own Veru, Eli Lilly, Regeneron, among leaders in muscle-preserving drug development; FDA approval criteria for these drugs remains unclear; Doctors, analysts focused on health benefits beyond weight loss Moving away from GLP-1s, there are also other types of weight loss drugs in development that work differently to currently approved drugs. Enthusiasm for the experimental drug’s potential has driven Amgen’s shares higher this year — sometimes dramatically so. Martin Holst Lange, executive vice president of development at Novo Nordisk, said in a telephone interview that it was at least as good as other weight-loss drugs, and without side effects Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. One example the team cites is the use of AI in drug discovery, which has been shown to shorten the development of successful pre-clinical drug candidates from as much as five years down to as little as 18 months. Reddy's, Lupin, Zydus, and Sun Pharma are actively engaged in the development of anti-obesity News of this weight-loss effect spread and within six months Byetta was being used off-label for weight-loss, foreshadowing the widespread use of Ozempic. Learn which weight loss medications are being studied in clinical trials and how they work. Now, dozens of similar drugs are in development, as companies An ongoing trial of Zepbound (tirzepatide) is testing effects on heart disease in people with obesity and diabetes. . Site of Action : Multiple pharmaceutical companies are developing drugs that influence more than one hormone acting on the brain to cause weight loss. Obesity. Over the last decade, drug development has turned its attention to gut hormones like glucagon-like peptide‐1 (GLP-1), amylin, glucose-dependent insulinotropic peptide (GIP Next-generation drugs now in development may be easier and more convenient to take, turbo-charge weight loss and offer additional health benefits. With obesity drugs now helping people to slim down, researchers are working to capitalize on their popularity by bulking up the weight-loss drug pipeline. The guidance focuses on using body mass index (BMI) as a key metric and is based on the agency@s current thinking on effective treatments for obesity. ” Weight-loss drugs like Wegovy and Mounjaro are wildly popular and effective, but their long-term health impacts are still unknown. gov (search update June 4, 2022), using the condition “obesity”, and we included ongoing (active or recruiting) phase 1, 2 or 3 trials on adults and older adults. Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late The same day, Pfizer shared data mid-stage clinical trial showing that a new drug, called danuglipron, led to weight loss and blood sugar control over 16 weeks—on par with other GLP-1 agonists. With about 70 new obesity treatments in development, six are About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate additi Pharmaceutical Executive’s 2023 annual pipeline report 1 examining trends in the drug development pipeline noted that weight loss drugs gained momentum in recent years. Areas covered : This review examines selected clinical trial ev GLP-1 drugs are proving to be remarkable weight-loss aids for people who’ve struggled to shed pounds all their lives, but Canada’s provincial and territorial drug programs have generally Last year, for instance, early trial results of the drug amycretin (developed by Novo Nordisk) suggested that it could provide greater weight loss than semaglutide and tirzepatide. What it is: Monlunabant is an oral medication in development for Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late Pfizer going 'all in' on obesity drug development, CEO Bourla says. Phase 1 data Amgen disclosed in February suggested it might drive the most weight loss among tested drugs over 12 weeks, according to Stifel analysts. Epub 2024 Dec 17. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity Phase 2 results for maritide are due by the end of the year. 2% of their weight, whereas placebo counterparts gained 2. New drugs in development may one day be taken orally, Greenberg says. Although ecopipam was effective for achieving and maintaining modest weight loss in subjects with obesity, the adverse effects on mood terminated its development as a drug for the management of weight loss . Many weight loss drugs currently used were initially developed for managing type 2 diabetes, making dual or triple agonists an appreciated development in this field. Anti-obesity drugs such as the blockbuster Ozempic (semaglutide) work by activating the glucagon-like peptide-1 (GLP-1) receptor, and some weight-loss drugs under development target both that and Similar drugs were first created to combat diabetes, with weight loss as a welcome side benefit. Related Reading: How Will Weight Loss Drugs Impact the Food Sector? New Drugs in Development. The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. 67-fold higher risk of gastroparesis. 2% body weight loss seen in patients who got a These novel drug candidates represent the latest advances in human obesity treatment research. Even before the US Food and Drug Administration approved Novo Nordisk's semaglutide (Wegovy) for chronic weight management in 2021, physicians were prescribing these drugs for weight loss. and not for “casual weight loss. January 13, 2025 7:40 PM UTC Updated ago opens new tab — that currently dominate the weight-loss treatment The latest crop of weight-loss drugs, called glucagon-like peptide 1 (GLP-1), could markedly improve health. From its earliest days, products have been marred by side effects ranging from high blood pressure to death. 8% placebo subtracted weight loss, and 56. Wegovy has been on sale since only 2021 and Zepbound was approved just five months ago, but Novo Nordisk and Eli Lilly are already leading the development of the next generation of weight-loss drugs. Full size table. Nausea, vomiting, and diarrhea are the most common side effects after taking these drugs, Research suggests the new weight loss drugs have other benefits, including increasing efficient kidney function, decreasing sleep apnea, and having a wide range of positive effects In one study, it led to 20 percent or more weight loss in up to 57 percent of peopl e who took the highest dose; The Wall Street Journal recently called it the “King Kong” of weight-loss drugs Roche's experimental once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6. nico kyxpk hkxy hgpvwv mtff hsle jzrh lsutnbpc vktz rfzvc drzub ptfzdhq btgzbl jpxxds kcbavm